A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

NCT05271409 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Interventions

DRUG: Satralizumab
OTHER: Placebo

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]